Table 4.

Effects of baseline CD4⁺ cell count (cells/μl) on mortality before and after excluding patients who did not meet antiretroviral treatment eligibility criteria at the time of antiretroviral treatment initiation^a.

	Asia and Americas		Sub-Saharan Africa
	Before exclusions	After exclusions	Before exclusions	After exclusions
Effect of baseline CD4+ cell count (cells/μl) on mortality in 1st 12 months
0–49	1.00	1.00	1.00	1.00
50–99	0.70 (0.62–0.80)	0.71 (0.62–0.80)	0.58 (0.56–0.60)	0.58 (0.56–0.60)
100–199	0.36 (0.31–0.41)	0.36 (0.31–0.41)	0.34 (0.33–0.35)	0.34 (0.33–0.34)
200–249	0.25 (0.20–0.30)	0.22 (0.18–0.29)	0.25 (0.24–0.26)	0.23 (0.22–0.25)
250–349	0.16 (0.13–0.19)	0.16 (0.13–0.19)	0.21 (0.20–0.22)	0.18 (0.17–0.19)
350–499	0.16 (0.13–0.20)	0.16 (0.12–0.20)	0.21 (0.20–0.22)	0.16 (0.14–0.19)
500+	0.15 (0.11–0.19)	0.10 (0.07–0.15)	0.17 (0.16–0.19)	0.13 (0.10–0.17)
Effect of baseline CD4+ cell count (cells/μl) on mortality after 1st 12 months
0–49	1.00	1.00	1.00	1.00
50–99	1.03 (0.90–1.18)	1.03 (0.90–1.18)	0.78 (0.75–0.81)	0.78 (0.74–0.82)
100–199	0.72 (0.63–0.82)	0.71 (0.63–0.81)	0.55 (0.53–0.56)	0.55 (0.53–0.57)
200–249	0.62 (0.52–0.73)	0.59 (0.49–0.72)	0.45 (0.43–0.48)	0.48 (0.44–0.52)
250–349	0.42 (0.36–0.50)	0.39 (0.33–0.47)	0.43 (0.41–0.45)	0.41 (0.39–0.44)
350–499	0.43 (0.36–0.53)	0.39 (0.31–0.49)	0.44 (0.41–0.48)	0.42 (0.36–0.49)
500+	0.45 (0.37–0.56)	0.33 (0.25–0.43)	0.36 (0.33–0.40)	0.24 (0.08–0.77)

ART, antiretroviral treatment.

^aIn Asia and the Americas, ART eligibility was assessed based on clinical and immunological criteria, depending on the published ART eligibility criteria for the country in the relevant year. In sub-Saharan Africa, ART eligibility was assessed based only on immunological criteria, due to incomplete recording of clinical stage. The results in the ‘After exclusions’ analysis are the same as those shown in Table 3.